title: Cathepsin D: Autoantibody profiling as a diagnostic marker for cancers.
abstract: Current diagnostic assays for many cancers are antigen-based and rely on the detection of circulating proteins that are associated with a particular cancer. These assays depend on the expression, synthesis, and release of specific proteins by cells (e.g., tumor cells) through either active secretion or shedding, or as a consequence of cell death (either necrosis or apoptosis). As such, these antigenic proteins must "escape" the primary site of disease, saturate the antigen-processing capacity of the individual's immune components, gain access to the circulation, and reach a sufficient steady-state concentration to be detected by enzyme- or radiolabel-based immunoassays. These events usually occur after the initial establishment of disease. Thus, and despite the fact that certain specific antigenic epitopes exhibit common recognition among patients with the same tumor types, the use of these antigen-based cancer assays has not been widely accepted in clinical practice, and many individual countries differ in the use of these potential diagnostic factors. Lately, an increasing number of studies demonstrated that procathepsin D secreted from cancer cells, acts as a mitogen on cancer cells and stimulates their pro-invasive and pro-metastatic properties. In this report, we focused on the possibility to use anti-procathepsin D autoantibodies as a diagnostic and/or predictive marker for cancers.
authors.affiliation: Vaclav Vetvicka, Department of Pathology, University of Louisville, Louisville, KY 40202, United States.
authors.forename: Vaclav
authors.initials: V
authors.lastname: Vetvicka
authors.forename: Martin
authors.initials: M
authors.lastname: Fusek
keywords: Autoantibodies; Cathepsin D; Diagnosis; Marker; Procathepsin D
references.citation: Cancer Res. 2010 Feb 15;70(4):1306-13
references.pmid: 20124478
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5287-312
references.pmid: 17954709
references.citation: Oncogene. 2002 Aug 29;21(38):5951-5
references.pmid: 12185597
references.citation: Anticancer Agents Med Chem. 2012 Feb;12(2):172-5
references.pmid: 22292775
references.citation: J Cell Mol Med. 2011 Oct;15(10):2013-24
references.pmid: 21651719
references.citation: APMIS. 1999 Jan;107(1):86-95
references.pmid: 10190284
references.citation: Cancer Gene Ther. 2002 Oct;9(10):854-63
references.pmid: 12224027
references.citation: Crit Rev Oncol Hematol. 2008 Oct;68(1):12-28
references.pmid: 18396408
references.citation: World J Clin Oncol. 2010 Nov 10;1(1):35-40
references.pmid: 21603309
references.citation: Clin Exp Metastasis. 2004;21(2):91-106
references.pmid: 15168727
references.citation: Biochem Biophys Res Commun. 2012 Apr 20;420(4):704-9
references.pmid: 22310721
references.citation: J Proteome Res. 2011 Jan 7;10(1):85-96
references.pmid: 20977275
references.citation: Ann Oncol. 2007 May;18(5):868-73
references.pmid: 17347129
references.citation: Int J Oncol. 2008 Feb;32(2):491-8
references.pmid: 18202773
references.citation: Cancer Immunol Immunother. 1998 Mar;46(1):48-54
references.pmid: 9520292